Celltrion’s COVID-19 antibody treatment applies for use in Korea
Treatment to be available in Korea from Feb., overseas applications to be filed in Jan. |
Celltrion’s CT-P59, also known as regdanvimab (Celltrion)
Local biologics company Celltrion on Tuesday filed for approval of its COVID-19 antibody treatment for use here, in what Seoul officials hope will be a new weapon in the country’s war against the new coronavirus in the absence of vaccines.
The Drug Ministry said it will attempt to review the safety and efficacy of the proposed COVID-19 treatment in the next 40 days.
If approved, the drug is anticipated to be ready for use in February in Korea.